Potential effect of probiotics in the treatment of breast cancer

Luis Mendoza

IQVIA, Prague, Czech Republic

Abstract

Breast cancer is one of the most important causes of cancer-related morbidity and mortality in the world. Probiotics, as functional food, have the potential to act against breast cancer, as evidenced by cell-based and animal model experiments. Probiotic may be useful in prevention or treatment of breast cancer by modulating the gastrointestinal bacteria and the systemic immune system. However, large-scale clinical trials and intensive research are mandatory to confirm the in vitro and in vivo results and exploring the probiotics-related metabolic, immune, and molecular mechanisms in breast cancer. This current review summarizes the available data related to probiotics and their potential role in the treatment of breast cancer.

Introduction

Breast cancer (BC) is the most frequent cancer in women, the second most common cancer worldwide, and the second primary cause of cancer-related deaths.1 One in eight women who live to age 85 years will develop BC over the course of their lifetime.2 Gastrointestinal (GI) tracts of humans and animals contain a complex community of bacteria, which has a deep interaction with host mucosal epithelial cells and immune cells in a bidirectional fashion.3 These microorganisms are helpful in physiologic activities such as digestion, metabolism, they metabolize bile acids and synthesize vitamins B and K, while their antigens and their metabolic products can stimulate production of cytokines against potential pathogens.3 The composition of the GI bacteria is highly dynamic, and internal or external factors can influence this population growth including age, race, diet, maternl colonization, international travel, infections and pharmaceuticals.4,5 Therefore, the bacteria composition and complexity tend to change in numbers and strains from the proximal to the distal GI tract during the lifetime. GI bacteria also play a crucial role in the development of homeostasis of the innate and adaptive immune system, and an alteration of its composition contributes to various diseases including metabolic disorders such as obesity and type 2 diabetes, autoimmune diseases such as rheumatoid arthritis, immune-related diseases such as atopy and asthma, and other disorders such as inflammatory bowel disease, irritable bowel syndrome and cancer.6-10 Epidemiological studies have shown an association between the overuse of antibiotics and an increased incidence of extra-colonic neoplasms, including BC, indicating that GI bacteria has a role in the carcinogenesis of local and distant tumors.11,12 Latest studies have reported that certain bacteria may improve the efficacy of some traditional anti-neoplastic drugs13 and of immunotherapies.14 The aim of this review was to compile the available information about the potential benefit of probiotics, modulating the GI bacteria and systemic immune system, in the treatment of BC.

Probiotics and cancer

The term probiotics has been used for several years, and their immunomodulatory effects were postulated by Nobel prize laureate Élie Metchnikoff over 100 years ago.15 Probiotics (bacteria or yeasts) were defined by the Food Agricultural Organization (FAO) and the World Health Organization (WHO) as live microorganisms which when administered in adequate amounts (in food or as a dietary supplement) confer a health benefit on the host.16 The most commonly used bacterial strains for probiotic purposes are the lactic acid bacteria, which are mainly consumed as fermented dairy products such as yogurt. Studies have shown that about 10-30% of probiotics survive in the GI tract, depending on a number of variables, including the type of probiotic17,18 and their resistance to acid pH and biliary acids to colonize the intestine.19 Probiotics have been found to reduce absorption of harmful mutagens that may contribute to the colon carcinogenesis20 or reducing the number of β-glucuronidase-expressing bacteria that transform pre-carcinogens into active carcinogens.21-27 In fact, several mechanisms have been proposed how probiotics may inhibit colon cancer; these include: enhancing the host’s immune response, altering the metabolic activity of the intestinal microflora, binding and degrading carcinogens, producing antimutagenic compounds, and altering the physiochemical conditions in the colon.28 Probiotics have been tested in animal tumor models confirming their ability to prevent colon cancer.29,30

GI bacteria and its role in the breast cancer tumorigenesis

GI bacteria plays an important role in the modulation, reabsorption, enterohepatic circulation, and modulation of
systemic estrogens. The GI bacteria has an association with estrogen levels through secretion of β-glucuronidase, an enzyme that deconjugates estrogen to its free, biologically active form available for tissue uptake. The increase in the amount of free estrogens for reabsorption contributes to the risk of development of hormone-driven malignancies such as BC. Interestingly, β-glucuronidase prevalence was also found in the nipple aspirate fluid of BC survivors. Data on the role β-glucuronidase and other fecal enzymes in BC risk are yet limited.

Diet, alcohol, and cholesterol metabolism, which are some risk factors associated with BC, have a direct influence on the GI bacteria and vice versa. Changes in the diet are known to affect the overall GI bacteria composition and function. Strict vegetarians have increased fecal excretion of conjugated estrogens compared with non-vegetarians, leading to decreased plasma estrogen concentrations and protect against subsequent BC risk. The activity of β-glucuronidase is also significantly lower in the vegetarians than in the omnivores. A strong association has been reported between the GI bacteria composition and the variation of blood lipid levels. Hypercholesterolemia is a risk factor for ER-positive BC. Cholesterol metabolite 27-hydroxycholesterol (27HC) has been shown to possess estrogenic activities and to promote breast tumor growth in xenograft mouse models. In humans, hypercholesterolemia and its role in breast carcinogenesis remains to be defined. Several small-scale studies reported lowered cholesterol on using probiotics, which may support their benefit in blocking the hypercholesterolemia-estrogen cancer mechanism.

Alcohol consumption alters the composition of the colonic microbiome in rats. There is an extensive information alcohol carcinogenesis remains to be defined. Several small-scale studies reported lowered cholesterol on using probiotics, which may support their benefit in blocking the hypercholesterolemia-estrogen cancer mechanism. Alcohol consumption alters the composition of the colonic microbiome in rats. There is an extensive information alcohol consumption increases the risk of ER-positive BC in postmenopausal women. Similarly, alcohol intake after BC diagnosis is associated with both increased risk of recurrence and death. Both GI anaerobic and aerobic bacteria are present at higher levels in subjects with chronic alcohol abuse and alcoholic cirrhosis compared with healthy controls.

The role of GI bacteria in estrogen deconjugation and the influence of women lifestyle seem to be contributors to the breast carcinogenesis. However, these observations need further study and more detailed definition.

**Effect of probiotics against BC in vitro and animal studies**

Numerous in vitro and animal studies have been carried out to investigate the effect of probiotics against BC. Table 1 shows some examples of these in vitro studies.

Several studies in animals have shown the benefit of probiotics against BC. Oral administration of *Lactobacillus acidophilus* in 0.5 mL suspension containing 2.7×10⁸ CFU/mL was given every day starting from two weeks before BC tumor transplantation and continued 30 days after with 3 days intervals. The results showed a significant increase in the survival time among the *L. acidophilus* group compared to that of the controls, demonstrating that this treatment can promote the immune responses via stimulation of the production of pro-inflammatory cytokines such as IFN-γ and inhibition of the production of anti-inflammatory cytokines such as IL-4 and IL-10. Additional animal studies confirmed that oral administration of *L. acidophilus* displays anticancer activity in mice bearing breast tumors.

In another study, 0.5 mL of this suspension containing 2.7×10⁸ CFU/mL *Lactobacillus casei* was orally administered to mice using a standard gastric feeding tube. The suspension was given

### Table 1. Examples of in vitro anticancer effect of probiotics in breast cancer cells.

| Probiotic stain                  | Cell line tested | Treatment and Duration | Results                                                                 | Ref  |
|---------------------------------|------------------|------------------------|----------------------------------------------------------------------|------|
| *Enterococcus lactis* IW5       | MCF-7            | Incubation with EL metabolites for 24 h | 30% cell inhibition                                                  | 57   |
| *Lactococcus lactis* NK34       | MCF-7            | Inoculation of 10⁵ or 10⁶ CFU/well of bacteria, incubated for 44 h | 59% and 98% cytotoxic effect at 10⁵ and 10⁶ CFU/well, respectively | 58   |
| *Lactococcus lactis* KC24       | MCF-7            | Inoculation of 10⁵ or 10⁶ CFU/well of bacteria, incubated for 48 h | Strong cytotoxic effect toward cancer cells | 59   |
| *Enterococcus faecalis* and     | MCF-7            | Incubation of 25, 50, 100 and 200 µg/mL | Significant inhibition of cell proliferation, induction of apoptosis and cell cycle arrest | 60   |
| *Staphylococcus hominis*        |                  | of live, heat killed cells or cytoplasmic fractions of bacteria for 24, 48 or 72 h | induction of apoptosis and cell cycle arrest |       |
| *Lactobacillus crispatus* and   | MCF-7            | Incubation and supernatant of various concentrations | Cytotoxic effect towards cells, together with suppression of hypoxi-inducible factor (HIF)-1 pathway | 61   |
| *Lactobacillus rhamnosus*       |                  |                        |                                                                      |      |
| Kefir grains water 50 mg/mL 4TI  | MTC assay        | Incubation with supernatant of various concentrations | Cytotoxic effect towards cells, together with suppression of hypoxi-inducible factor (HIF)-1 pathway | 62   |
| (mix of *Lactobacillus acidophilus*, *Lactobacillus casei*, and *Lactococcus lactis*) |                      |                        |                                                                      |      |
| *Lactobacillus plantarum*       | MDA-MB-231       | Various concentration | Apoptosis was mediated by downregulation of the NFκB pathway           | 63   |
| *Lactobacillus crispatus* and   | MDA-MB-231       | MTT assay               | Antiproliferative activity; lactobacilli can decrease transcriptional activity of four different cancer-testis antigens | 64   |
| *Lactobacillus acidophilus*     |                  |                        |                                                                      |      |

**MTT assay** [3-(4,5-dimethylthiazol-2-y-2,5-diphenyltetrazolium bromide] assay.
daily for two consecutive weeks before subcutaneous transplantation of adenocarcinoma breast tumor into mice. The administration then continued for three weeks with a 3-day interval between each week. Data analysis showed a significant decrease in the growth rate of tumors and the survival was significantly prolonged compared to the controls. The study has concluded that oral administration of *L. casei* can affect stimulation of the Th1 cytokine production in mouse spleen cell culture and NK cell cytotoxicity.67

Oral administration of fermented milk containing *Lactobacillus helveticus* R389 demonstrated an immunoregulatory response in BC-bearing mice and suggested its use as immune adjuvant therapy to protect against malignancies.68 In mice treated with selenium nanoparticles enriched with *Lactobacillus plantarum*, an increase of IFN-γ and IL-2 levels was reported, but the animals also showed enhanced NK cell activity.69 Furthermore, oral administration of selenium nanoparticles enriched with *Lactobacillus brevis* seemed to be related with better disease prognosis among highly metastatic breast tumor-bearing mice.70

A Slovakian group demonstrated the chemopreventive efficacy of a new probiotic bacterial strain, *Lactobacillus plantarum* LS/07, in a rat model of BC. Mammary carcinogenesis was induced by 7,12-dimethylbenz[a]anthracene (DMBA). *Lactobacillus plantarum* LS/07 (at a dose of 8.4×10^8 CFU/rat) was administered daily before the first DMBA dose and given until the end of the experiment (16 weeks). The treatment with the probiotics significantly suppressed the tumor frequency, increased CD4+ T-cells in tumor tissue, and reduced the serum tumor necrosis factor (TNF)-α concentration and the level of CD8+ T-cells in the blood while increasing their number in tumor tissue.71

A natural product, Kefir, is a unique cultured product that contains beneficial probiotics. Kefir grains contain various kinds of microbial flora, including the most commonly studied species with probiotic potential such as *L. acidophilus*, *L. casei*, and *Lactococcus lactis*.72,73 In another animal experiment, the kefir grains were fermented for 24 h at room temperature. After that, the grains were filtered out from the fermented medium. Mice with tumors were fed orally with kefir water (150 mg/kg body weight per day). All mice in the tumor group were inoculated with 1×10^5 4T1 triple-negative 4T1 murine BC cells subcutaneously, and treatment was administrated orally on the same day as the tumor inoculation for 28 days. The tumor size in kefir water-treated mice was smaller than that in untreated mice. The tumor weight and volume were also reduced significantly by 29.53% and 32.92%, respectively, in kefir water-treated mice as compared to the untreated mice. Kefir water exhibited antimetastatic and antiangiogenesis effects in 4T1 cell-challenged mice *in vivo* through reducing 4T1 cell mitosis, promoting apoptosis, modulating immune systems, inhibiting inflammation in the tumor microenvironment, and regulating angiogenesis-related proteins and genes.74

**Clinical trials**

Probiotics in a colon cancer clinical trial has shown a benefit for post-operative complications, therapy-related toxicity and improving the quality of life.75 Recently, a cohort study with 12-year follow up of 45,241 volunteers determined that high yogurt intake (*Streptococcus thermophilus* and *Lactobacillus delbrueckii*) was significantly associated with decreased colon cancer risk.76 Probiotics have also shown the ability to prevent the recurrence of superficial bladder cancer.77

*In vitro* and *in vivo* studies have provided evidence that probiotics display activity against BC. However, only a few clinical trials have been done in these patients. In a Japanese population-based case-control study, 306 cases with BC and 662 controls aged 40 to 55 years were investigated about their diet, lifestyle, and other BC risk factors using a self-administered questionnaire and interview. It was concluded that regular consumption of *L. casei* Shirota and soy isoflavones since adolescence was significantly associated with decreased BC risk in Japanese women.78 Therefore, long-term exposure was required to accomplish a chemopreventive effect on cancer development.

The clinicaltrial.gov web page has registered just two ongoing clinical trials studying the benefit of probiotics in BC patients. The first trial, NCT03358511, is a single experimental arm studying the number of cytotoxic T lymphocytes (CD8+ cells) in BC subjects treated with probiotics. Twenty post-menopausal BC subjects will be given 2-4 weeks of probiotics prior to surgery in operable stage I-III breast adenocarcinoma tumors ≥1.0 cm. Subjects will take the probiotics three times a day. The probiotic under study is Primal Defense® ULTRA (Garden of Life LLC, USA), which is an overt-the-counter probiotic that provides 15 billion colony-forming units of 13 species of beneficial bacteria. The second study, NCT03760653, is a randomized controlled pilot study to determine the effects of physical exercise together with supplementation of a probiotic on the GI bacteria balance, GI immune system and the quality of life in 30 BC survivors. BC survivors will be randomly assigned to each of the three groups: i) probiotic supplementation + supervised combined physical exercise; ii) probiotic supplementation and habitual sedentary lifestyle; and iii) a control group following the usual lifestyle and receiving a placebo. The two supplemented groups will take three capsules (*Lactobacillus rhamnosus*, *Lactobacillus paracasei*, *Lactobacillus acidophilus*, *Bifidobacterium bifidum*) a day (at night before bedtime) for 12 weeks.

So far, there is just a few already executed or running clinical trials testing probiotics in BC patients, and no prospective studies about the efficacy of probiotics in the BC prevention or treatment have been planned.

**Conclusions**

Oral probiotics display a vast range of beneficial properties and have gained an increasing medical importance over the last decade. Presently, it is believed that many of the commercially available probiotic products are safe to use and have beneficial health effects for the host. In this paper, we have reported the potential of oral probiotics against BC confirmed by human BC cell-based and animal experiments. The results on animal studies indicate that probiotics may have an anticancer systemic property, enhancing the systemic immune system, useful for interventions to prevent and control progression of BC. Although, other different mechanisms may be involved in these beneficial effects, mainly due to the modulation by the GI bacteria and subsequently the suppression of carcinogenesis in the breast. More clinical research from the academia and industry is necessary to establish the value of probiotics and understanding of their immune mechanisms in the prevention and treatment of patients with BC. There is a road ahead to identify the bacterium or bacteria strains active against to the malignancy, the probiotics dosages and treatment schemes may bring a benefit for different BC types, stages and settings.
References

1. Evans DG, Howell A. Breast cancer risk-assessment models. Br Cancer Res 2007;9:213.
2. Siegel RL, Miller KD, Jemal A. Cancer statistics. CA Cancer J Clin 2018;68:7-30.
3. Sherwood L, Willey J, Woolverton C. Prescott’s Microbiology 9th Edition. New York: Mc Graw Hill; 2013.
4. Sekirov I, Russell SL, Antunes LC, Finlay BB. Gut bacteria in health and disease. Physiol Rev 2010;90:859-904.
5. Lu K, Mahbub R, Fox JG. Xenobiotics: interaction with the intestinal microflora. ILAR J 2015;56:218-27.
6. Ley RE, Turnbaugh PJ, Klein S, Gordon JI. Microbial ecology: human gut microbes associated with obesity. Nature 2006;444:1022-3.
7. Manichanh C, Borrelut N, Casellas F, Guanier F. The gut bacteria in IBD. Nat Rev Gastroenterol Hepatol 2012;9:599-608.
8. Vaathovuo J, Munukka E, Korkeamäki M, et al. Fecal bacteria in early rheumatoid arthritis. J Rheumatol 2008;35:1500-5.
9. Russell SL, Gold MJ, Hartmann M, et al. Early life antibiotic-driven changes in bacteria enhance susceptibility to allergic asthma. EMBO Rep 2012;13:440-7.
10. Dinan TG, Cryan JF. The impact of gut bacteria on brain and behaviour: implications for psychiatry. Curr Opin Clin Nutr Metab Care 2015;18:552-8.
11. Xuan C, Shamonki JM, Chung A, et al. Microbial dysbiosis is associated with human breast cancer. PLoS One 2014;9:e83744.
12. Velicer CM, Heckbert SR, Lampe JW, et al. Antibiotic use in relation to the risk of breast cancer. J Am Med Assoc 2004;291:827-35.
13. Viaud S, Saccheri F, Mignot G, et al. The intestinal bacteria modulates the anticancer immune effects of cyclophosphamide. Science 2013;342:971-6.
14. Mendoza L. Influence of gastrointestinal flora in the treatment of cancer with immune checkpoint inhibitors. Klin Onkol 2018;31:465-7.
15. Mackowiak PA. Recycling Metchnikoff: probiotics, the gut microbiome, and breast cancer pathophysiology. Science 2013;342:1094-8.
16. Marteau P, Minekus M, Havenaar R, et al. Survival of lactic acid bacteria in a dynamic model of the stomach and small intestine: validation and the effects of bile. J Dairy Sci 1997;80:1031-7.
17. Marteau PR, de Vrese M, Cellier CJ, Schrezenmeir J. Protection from gastrointestinal diseases with the use of probiotics. Am J Clin Nutr 2001;73:430S-6S.
18. Marteau P, Minekus M, Havenaar R, et al. Survival of lactic acid bacteria in yogurt and milk. Am J Clin Nutr 1979;32:19-24.
19. Goldin BR, Adlercreutz H, Gorbach SL, et al. Estrogen metabolism, and breast cancer. N Engl J Med 2014;370:572-8.
20. Goldin BR, Swenson L, Dwyer J, et al. Effect of diet and Lactobacillus acidophilus supplements on human fecal bacterial enzymes. J Natl Cancer Inst 1980;64:255-61.
21. Goldin BR, Gorbach SL. The effect of milk and Lactobacillus feeding on human intestinal bacterial enzyme activity. Am J Clin Nutr 1984;9:756-61.
22. Ling WH, Korpela R, Mykkänen H, et al. Lactobacillus strain GG supplementation decreases colonic hydrolytic and reductive enzyme activities in healthy female adults. J Nutr 1994;124:18-23.
23. Bouhnik Y, Attar A, Joly FA, et al. Lactulose ingestion increases faecal bifidobacterial counts: a randomised double-blind study in healthy humans. Eur J Clin Nutr 2004;58:462-6.
24. Guerin-Danan C, Chabanet C, Pedone C, et al. Milk fermented with yogurt cultures and Lactobacillus casei compared with yogurt and gelled milk: influence on intestinal microflora in healthy infants. Am J Clin Nutr 1998;67:111-7.
25. Spanhaak S, Havenaar R, Schaafsma G. The effect of consumption of milk fermented by Lactobacillus casei strain Shirota on the intestinal microflora and immune parameters in humans. Eur J Clin Nutr 1998;52:899-907.
26. Hirayama K, Rafter J. The role of probiotic bacteria in cancer prevention. Microbes Infect 2000;2:681-6.
27. Liong MT. Roles of probiotics and prebiotics in colon cancer prevention: postulated mechanisms and in-vivo evidence. Int J Mol Sci 2008;9:854-63.
28. Capurso G, Marignani M, Delle Fave G. Probiotics and the incidence of colorectal cancer: When evidence is not evident. Dig Liver Dis 2006;38:S277-82.
29. Gadelle D, Raibaud P, Sacquet E. Beta-Glucuronidase activities of intestinal bacteria determined both in vitro and in vivo in gnotobiotic rats. Appl Environ Microbiol 1985;49:682-5.
30. Gloux K, Berteau O, El Oumami H, et al. A metagenomic beta-glucuronidase uncovers a core adaptive function of the human intestinal microbiome. Proc Natl Acad Sci U S A 2011;108:4539-46.
31. McIntosh FM, Maison N, Holtrop G, et al. Phylogenetic distribution of genes encoding beta-glucuronidase activity in human colonic bacteria and the impact of diet on faecal glycosidase activities. Environ Microbiol 2012;14:1876-87.
32. Kwa M, Plottel CS, Blaser MJ, Adams S. The intestinal microbiome and estrogen receptor - positive female breast cancer. J Natl Cancer Inst 2016;108:djw029.
33. Chan AA, Bashir M, Rivas MN, et al. Characterization of the microbiome of nipple aspirate fluid of breast cancer survivors. Sci Rep 2016;6:28061.
34. Muegge BD, Kuczynski J, Knights D, et al. Diet drives convergence in gut microbiome functions across mammalian phylogeny and within humans. Science 2011;332:970-4.
35. Goldin BR, Adlercreutz H, Gorbach SL, et al. Estrogen excretion patterns and plasma levels in vegetarian and omnivorous women. N Engl J Med 1982;307:1542-7.
36. Gorbach SL, Goldin BR. Diet and the excretion and enterohepatic cycling of estrogens. Prev Med 1987;16:525-31.
37. Fu J, Bonder MJ, Cenit MC, et al. The gut microbiome contributes to a substantial proportion of the variation in blood lipids. Circ Res 2015;117:817-24.
38. Wu Q, Ishikawa T, Sirlam R, et al. 27-Hydroxycholesterol promotes cell-autonomous, ER-positive breast cancer growth. Cell Rep 2013;5:637-45.
39. Nelson ER, Wardell SE, Jasper JS, et al. 27-Hydroxycholesterol links hypercholesterolemia and breast cancer pathophysiology. Science 2013;342:1094-8.
40. Warner M, Gustafsson JA. On estrogen, cholesterol metabolism, and breast cancer. N Engl J Med 2014;370:572-3.
41. Hopenhayn-Rich C, Fried R, St Jeor S, et al. Hypocholesterolemic effect of yogurt and milk. Am J Clin Nutr 1979;32:19-24.
42. Hlivak P, Odraska J, Ferencik M, et al. One-year application of
probiotic strain Enterococcus faecium M-74 decreases serum cholesterol levels. Bratisl Lek Listy 2005;106:67-72.
45. Boyd NF, McGuire V. Evidence of association between plasma high-density lipoprotein cholesterol and risk factors for breast cancer. J Natl Cancer Inst 1990;82:460-8.
46. Mutlu E, Keshavarzian A, Engen P, et al. Intestinal dysbiosis: a possible mechanism of alcohol-induced endotoxemia and alcoholic steatohepatitis in rats. Alcohol Clin Exp Res 2009;33:1836-46.
47. Willett WC, Stampfer MJ, Colditz GA, et al. Moderate alcohol consumption and the risk of breast cancer. N Engl J Med 1987;316:1174-80.
48. Lew JQ, Freedman ND, Leitzmann MF, et al. Alcohol and risk of breast cancer by histologic type and hormone receptor status in postmenopausal women: the NIH-AARP Diet and Health Study. Am J Epidemiol 2009;170:308-17.
49. Li CI, Chlebowski RT, Freiberg M, et al. Alcohol consumption and risk of postmenopausal breast cancer by subtype: the women's health initiative observational study. J Natl Cancer Inst 2010;102:1422-31.
50. Deandrea S, Talamin R, Foschi R, et al. Alcohol and breast cancer risk defined by estrogen and progesterone receptor status: a case-control study. Cancer Epidemiol Biomarkers Prev 2008;17:2025-8.
51. Suzuki R, Orsini N, Migione L, et al. Alcohol intake and risk of breast cancer defined by estrogen and progesterone receptor status—a meta-analysis of epidemiological studies. Int J Cancer 2008;122:1832-41.
52. Frydenberg H, Flote VG, Larsson IM, et al. Alcohol consumption, endogenous estrogen and mammographic density among premenopausal women. Breast Cancer Res 2015;17:103.
53. Kwan ML, Kushi LH, Weltzien E, et al. Alcohol consumption and breast cancer recurrence and survival among women with early-stage breast cancer: the life after cancer epidemiology study. J Clin Oncol 2010;28:4410-6.
54. Bode JC, Bode C, Heidelbach R, et al. Jemnial microflora in patients with chronic alcohol abuse. Hepatogastroenterology 1984;31:30-4.
55. Casafont Morencos F, de las Heras Castano G, Martin Ramos L, et al. Small bowel bacterial overgrowth in patients with alcoholic cirrhosis. Dig Dis Sci 1996;41:552-6.
56. Mutlu EA, Gillevet PM, Rangwala H, et al. Colonic microbiome is altered in alcoholism. Am J Physiol Gastrointest Liver Physiol 2012;302:G966-78.
57. Nami Y, Haghshenas B, Haghshenas M, et al. The prophylactic effect of probiotics Enterococcus lactis IW5 against different human cancer cells. Front Microbiol 2015;6:1317.
58. Han K, Lee N, Park H et al. Anticancer and anti-inflammatory activity of probiotic Lactococcus lactis NK34. J Microbiol Biotechnol 2015;25:1697-701.
59. Lee-N-K, Han KJ, Son S-H, et al. Multifunctional effect of probiotic Lactococcus lactis KC24 isolated from Kimchi. LWT Food Sci Technol 2015;64:1036-41.
60. Hassan Z, Mustafa S, Rahin RA, et al. Antibreast cancer effect of live, heat-killed and cytoplasmic fractions of Enterococcus faecalis and Staphylococcus hominis isolated from human breast milk in vitro. Cell Dev Biol Anim 2016;5:337-48.
61. Bharti V, Mehta ASS, Jain N, Ahirwal L. Cytotoxicity of the live whole cells, heat-killed cell and cell free extract of lactobacillus strain in U-87 human glioblastoma cells line and MCF-7 breast cancer cell line. Int J Probiotics Prebiotics 2015;10:153-8.
62. Zamberi NR, Abu N, Mohamed NE, et al. The Antimetastatic and Antiangiogenesis Effects of Kefir Water on Murine Breast Cancer Cells. Integr Cancer Ther 2016;15:NP53-NP66.
63. Kadirareddy RH, Vemuri SG, Palampalli UM. Probiotic conjugated linoleic acid mediated Apoptosis in breast cancer cells by downregulation of NFkB. Asian Pac J Cancer Prev 2016;17:3395-403.
64. Modarressi RE, Daneshvar M, Beigom M, Mobasheri EM. Lactobacillus Acidophilus and Lactobacillus Crispatus Culture Supernatants Downregulate Expression of Cancer-Testis Genes in the MDA-MB-231 Cell Line. Asian Pacific J Cancer Prev 2014;15:4255-9.
65. Imani Fooladi A, Yazdi M, Pourmand M, et al. Th1 Cytokine Production Induced by Lactobacillus acidophilus in BALB/c Mice Bearing Transplanted Breast Tumor. Jundishapur J Microbiol 2015;8:e17354.
66. Yazdi MH, Soltan Dallal MM, Hassan ZM, et al. Oral administration of Lactobacillus acidophilus induces IL-12 production in spleen cell culture of BALB/c mice bearing transplanted breast tumour. Br J Nutr 2010;104:227-32.
67. Soltan Dallal MM, Yazdi MH, Holakuyee M, et al. Lactobacillus caseli spss.cased induced Th1 cytokine profile and natural killer cells activity in invasive ductal carcinoma bearing mice. JIAAI 11(2):183-9.
68. de Moreno A, Matar C, LeBlanc N, and Perdigon G. Effects of Milk Fermented by Lactobacillus Helveticus R389 on a Murine Breast Cancer Model. Breast Cancer Res 2005;7:477-86.
69. Yazdi MH, Mahdavi M, Kheradmand E, Shahverdi AR. The preventive oral supplementation of a selenium nanoparticle enriched probiotic increases the immune response and lifespan of 4T1 breast cancer bearing mice. Arzneimittel-Forschung 2012;62:525-31.
70. Yazdi MH, Mahdavi M, Setayesh N, et al. Nanoparticle-enriched, S. Lactobacillus Brevis causes more efficient immune responses in-vivo and reduces the liver metastasis in metastatic form of mouse breast cancer. DARU J Pharm Sci 2013;21:33.
71. Kassayova M, Bobrov N, Strojny L, et al. Preventive effects of probiotic bacteria Lactobacillus plantarum and dietary fiber in chemically induced mammary carcinogenesis. Anticancer Res 2014;34:4969-76.
72. Otiles S, Cagindri O, Akcicek E. Probiotics and health. Asian Pac J Cancer Prev 2003;4:369-72.
73. Kakisu E, Irigoyen A, Torre P, et al. Physicochemical, microbiological and sensory profiles of fermented milk containing probiotic strains isolated from kefir. J Dairy Res 2011;78:456-63.
74. Zamberi NR, Abu N, Mohamed NE, et al. The antimetastatic and antiangiogenesis effects of Kefir water on murine breast cancer cells. Int J Cancer Ther 2016;15:NP53-NP66.
75. Serban DE. Gastrointestinal cancers: Influence of gut bacteria, probiotics and prebiotics. Cancer Lett 2014;345:258-70.
76. Pala V, Siesi S, Berino F et al. Yogurt consumption and risk of colorectal cancer in italian EPIC cohort. Int J Cancer 2014;29:2712-9.
77. Aso Y, Akaza H, Kotake T, et al. Preventive effect of a lactobacillus casei preparation in the prevention on the recurrence of superficial bladder cancer ina double blind trial. Eur Urol 1995;27:104-9.
78. Toi M, Horota S, Tomotaki A, et al. Probiotics beverage with soy isoflavone consumption for breast cancer prevention: A case-control study. Curr Nutr Food Sci 2013;9:194-200.